CLINICAL EFFECTS OF SHEXIANGBAOXIN PILLS ON THE STABLE ANGINA PECTORIS OF QI STAGNATION AND BLOOD STASIS SYNDROME AND ITS INFLUENCE ON CK-MB, ROS AND HAEMORHEOLOGY

Leilei Guo¹, Yijin Xie², Linbao Wen^{2, *}

¹Department of Cardiology, Guizhou University of Traditional Chinese Medicine, Gui’an New District 550025, PR China - 2Department of Neurosurgery, Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550001, PR China

Objective: To analyse the clinical efficacy of ShexiangBaoxin pills (HMP) in the treatment of stable angina pectoris (SAP) with qi stagnation and blood stasis syndrome as well as its influence on CK-MB, ROS and haemorheology.

Methods: A total of 98 SAP patients treated in our hospital from March 2018 to April 2019 were selected and randomly divided into observation and control groups, with 49 cases per group. All patients received conventional drug treatment (i.e., isosorbide dinitrate and simvastatin) after admission. The control group was treated with aspirin based on conventional drug treatment, while the observation group was treated with HMP based on conventional drug treatment. The symptoms of qi stagnation and blood stasis syndrome, angina pectoris attack, clinical efficacy, CK-MB, ROS, blood viscosity ratio and haemorheology were compared between the two groups before and after treatment.

Results: The total effective rate of the observation group was 87.76%, while that of the control group was 63.27%. The difference between the two groups was statistically significant (P<0.05). After treatment, the scores for chest pain, chest tightness, shortness of breath and palpitation symptoms in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the number of angina pectoris attacks per week and the duration of each attack in the observation group were significantly higher than those in the control group, while the levels of CK-MB and ROS in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the blood viscosity ratio of the observation group was significantly lower than that of the control group at 1.0, 5.0 and 35.0s-1 (P<0.05). After treatment, the erythrocyte deformation index of the observation group was significantly higher than that of the control group (P<0.05), while the erythrocyte aggregation index was significantly higher than that of the control group (P < 0.05). It decreased significantly (P<0.05).

Conclusion: HMP is effective in the treatment of SAP with qi stagnation and blood stasis syndrome, which can significantly improve angina pectoris and its related symptoms while improving the remission rate.